New research disproves belief that group psychotherapy extends the lives of cancer patients

May 01, 2007

Previously-published research has given credence to the notion that psychotherapy extends the lives of people with cancer. In fact, one in four cancer patients believe that science supports the idea that participating in group therapy will extend their lives. However, in a paper appearing in the May issue of the Psychological Bulletin, researchers at the University of Pennsylvania School of Medicine concluded - after an extensive research review - that there is no compelling evidence linking psychotherapy or support groups with survival among cancer patients.

"We all wish that psychotherapy could prolong life, because it appeals so strongly to firmly-rooted notions that a person should be able to control their destiny," says lead author, James C. Coyne, PhD, Co-Leader, Cancer Control and Outcomes Program, Abramson Cancer Center and Professor of Psychology in Psychiatry at Penn. "We have a special responsibility to cancer patients to clarify that the reasonable goal of psychotherapy and support groups is to improve their quality of life, not extend it."

Two studies in particular - Spiegel et al., 1989 and Fawzy et al., 1993 - have been widely interpreted as providing early support for the idea that psychotherapy promotes survival among cancer patients. However, the authors report that the studies had numerous methodological and analytical flaws, including the fact that they were not designed to test the hypothesis that psychotherapy extends the lives of cancer patients. The study investigators had redefined the purpose of their studies after looking at their data - a practice that is generally not acceptable in biomedicine and that often leads to claims that will not be validated in subsequent studies.

Coyne notes, "If these studies had been testing medications, rather than psychotherapy, no one would have paid much attention to the redefined outcome of improved survival, and leading medical journals would probably not have accepted the papers, given their other flaws."

In the years following these studies, additional studies have been conducted to test for the effect of psychotherapy extending the lives of cancer patients, but none have demonstrated a survival benefit that could logically be attributed to psychotherapy. In biomedicine, a large-scale trial would not be considered warranted for cases in which a hypothesis was interesting but improbable given the available data. Therefore, the authors conclude that there is not enough basis to justify investing additional funding for research in this area.
-end-
Additional authors of this research review are Steven C. Palmer, PhD, Abramson Cancer Center of the University of Pennsylvania and Department of Psychiatry; and Michael Stefanek, PhD, American Cancer Society.

PENN Medicine is a $2.9 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals, all of which have received numerous national patient-care honors [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.

University of Pennsylvania School of Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.